The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders

scientific article published on 2 February 2018

The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.PHRS.2018.01.021
P698PubMed publication ID29408302

P50authorRobert RoskoskiQ62562844
P577publication date2018-02-02
P1433published inPharmacological ResearchQ15724622
P1476titleThe role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders

Reverse relations

cites work (P2860)
Q55091809A new apatinib microcrystal formulation enhances the effect of radiofrequency ablation treatment on hepatocellular carcinoma.
Q50297836Autophosphorylation of PDGF alpha receptors
Q100152579Autophosphorylation of PDGFR mutant dimers
Q64103369Comparable Genomic Copy Number Aberrations Differ across Astrocytoma Malignancy Grades
Q100166457Drug resistance of PDGFR mutants
Q90747772Ellagic Acid, Kaempferol, and Quercetin from Acacia nilotica: Promising Combined Drug With Multiple Mechanisms of Action
Q89883760Foretinib Inhibits Cancer Stemness and Gastric Cancer Cell Proliferation by Decreasing CD44 and c-MET Signaling
Q100152581GRB2:SOS1 complex binds to mutant PDGFR receptor
Q100166452Imatinib-resistant PDGFR mutants
Q100152616Imatinib-resistant PDGFR mutants don't bind imatinib
Q92908301Impaired adrenergic agonist-dependent beige adipocyte induction in obese mice
Q100152578Ligand-independent dimerization of PDGFR mutants
Q89701164MFAP2 is overexpressed in gastric cancer and promotes motility via the MFAP2/integrin α5β1/FAK/ERK pathway
Q57074551MicroRNA-140-3p enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting pregnenolone X receptor
Q50297834PDGF dimer binds two receptors simultaneously
Q58803894PDGF/PDGFR effects in osteosarcoma and the "add-on" strategy
Q100166451PDGFR mutants bind TKIs
Q100152613PDGFR mutants bind type I TKIs
Q100152611PDGFR mutants bind type II TKIs
Q100157997PDGFRs bind type I TKI
Q100157998PDGFRs bind type II TKI
Q100152586PI3-kinase binds to mutant PDGFR receptor
Q100152585SOS-mediated nucleotide exchange of RAS downstream of mutant PDGFR receptors
Q90068745SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity
Q100166459Signaling by PDGFR in disease
Q100166443Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
Q100166453Sunitinib-resistant PDGFR mutants
Q64253749Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys"
Q90427365The TGF-β/Smad Pathway Inhibitor SB431542 Enhances The Antitumor Effect Of Radiofrequency Ablation On Bladder Cancer Cells
Q90355638The effects of focal adhesion kinase and platelet-derived growth factor receptor beta inhibition in a patient-derived xenograft model of primary and metastatic Wilms tumor
Q58109286Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma

Search more.